二甲双胍抑制人MDA-MB-231细胞增殖及迁移的体外实验研究

doi:10.3969/j.issn.1004-616x.2022.01.007

摘要/Abstract

摘要： 目的： 研究二甲双胍对体外培养的人三阴性乳腺癌MDA-MB-231细胞增殖及迁移的影响。方法： MTT实验分为4个处理组，分别为RPMI 1640培养基对照组，浓度为1、2、4 mmol/L的二甲双胍处理组，在作用48、72 h后测定各组的细胞活力并进行统计学分析；倒置相差显微镜下观察药物处理72 h后人乳腺癌MDA-MB-231细胞与对照组相比的形态变化；Giemsa染色观察4 mmol/L二甲双胍作用48 h后的细胞形态；采用细胞划痕实验和Transwell实验，检测二甲双胍（2、4 mmol/L）作用人乳腺癌MDA-MB-231细胞24 h后，对细胞迁移能力的影响。结果： MTT实验结果显示4 mmol/L二甲双胍作用72 h可显著抑制MDA-MB-231细胞的活力，抑制率为（29.83±2.25）％，与对照组相比，细胞活力降低（P<0.05）。倒置相差显微镜下形态学观察发现，与对照组相比，4 mmol/L二甲双胍处理组细胞密度降低，变圆的细胞数量增加，细胞与细胞之间的联系减少。Giemsa染色结果显示4 mmol/L二甲双胍作用48 h后，部分细胞出现凋亡细胞核碎裂形态。划痕实验结果表明，2、4 mmol/L二甲双胍作用24 h后细胞汇合度明显低于对照组，其中4 mmol/L处理组的划痕愈合率为（52.67±4.48）%，与对照组间的差异显著（P<0.01）；Transwell实验结果表明，2、4 mmol/L二甲双胍作用细胞24 h后穿膜细胞数量减少，穿膜细胞数量分别为（61.6±1.6）、（51.3±2.6）个，均低于对照组的（99.3±18.9）个（P<0.05）。结论： 二甲双胍在体外可抑制人乳腺癌MDA-MB-231细胞的增殖及迁移。

关键词: 二甲双胍, 体外实验, 乳腺癌, MDA-MB-231细胞, 细胞增殖, 细胞迁移

Abstract: OBJECTIVE: To investigate effects of metformin on proliferation and migration of human breast cancer cell MDA-MB-231 in vitro. METHODS: Cell cultures were divided into four treatment groups:RPMI 1640 medium group and metformin treatment groups (1,2,4 mmol/L). Cell viability was measured at 48 and 72 h after treatment. Morphological changes of cells were observed under inverted microscopes after cells were stained with Giemsa. Effects of metformin on cell migration were detected by wound healing and Transwell assays. RESULTS: The MTT assay showed that metformin at 4 mmol/L significantly inhibited cell viability l for 72 h,and the inhibition rate was (29.83±2.25%). Compared with the control group,the decrease of cell viability was statistically significant (P<0.05). In the 4 mmol/L treatment group,the number of round cells increased,the cell density decreased obviously,and the connection between cells decreased. After treatment with metformin at 4 mmol/L for 48 hours,the cells showed obvious nuclear fragmentation. Wound healing experiment showed that the cell confluence of 2,4 mmol/L treatment groups were obviously lower than that of the control group after 24 h. The wound healing rate of 4 mmol/L treatment group was (52.67±4.48%),which was significantly different from that of the control group (P<0.01). Transwell experiments showed that the number of perforating cells decreased after treated with metformin at the concentration of 2,4 mmol/L for 24 h. The numbers of perforating cells were (61.6±1.6) and (51.3±2.6),which was significantly different from that of the control group (99.3±18.9) (all P<0.05). CONCLUSION: Metformin inhibited proliferation and migration of human breast cancer cell in vitro.

Key words: metformin, in vitro, human breast cancer, MDA-MB-231 cell, cell proliferation, cell migration

中图分类号:

R730.5

赵岩, 孙震晓. 二甲双胍抑制人MDA-MB-231细胞增殖及迁移的体外实验研究[J]. 癌变·畸变·突变, 2022, 34(1): 35-39.

ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39.

参考文献

[1] ROJAS L B, GOMES M B. Metformin:an old but still the best treatment for type 2 diabetes[J]. Diabetol Metab Syndr, 2013, 5(1):6.
[2] COYLE C, CAFFERTY F H, VALE C, et al. Metformin as an adjuvant treatment for cancer:a systematic review and meta-analysis[J]. Ann Oncol, 2016, 27(12):2184-2195.
[3] EMAMI RIEDMAIER A, FISEL P, NIES A T, et al. Metformin and cancer:from the old medicine cabinet to pharmacological pitfalls and prospects[J]. Trends Pharmacol Sci, 2013, 34(2):126-135.
[4] RAJH M, DOLINAR K, MIŠ K, et al. Medium renewal blocks anti-proliferative effects of metformin in cultured MDA-MB-231 breast cancer cells[J]. PLoS One, 2016, 11(5):e0154747.
[5] KATO K, GONG J, IWAMA H, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo[J]. Mol Cancer Ther, 2012, 11(3):549-560.
[6] LECLERC G M, LECLERC G J, KUZNETSOV J N, et al. Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts[J]. PLoS One, 2013, 8(8):e74420.
[7] YUE W, YANG C S, DIPAOLA R S, et al. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment[J]. Cancer Prev Res:Phila, 2014, 7(4):388-397.
[8] KOBAYASHI M, KATO K, IWAMA H, et al. Antitumor effect of metformin in esophageal cancer:in vitro study[J]. Int J Oncol, 2013, 42(2):517-524.
[9] ZHANG B, LIU L L, MAO X, et al. Effects of metformin on FOXM1 expression and on the biological behavior of acute leukemia cell lines[J]. Mol Med Rep, 2014, 10(6):3193-3198.
[10] 方雪娇, 徐建昕, 王思萱, 等. 二甲双胍通过下调c-Myc增强人乳腺癌MDA-MB-231细胞对他莫昔芬的敏感性[J]. 中国病理生理杂志, 2019, 35(5):769-776.
[11] VAGIA E, MAHALINGAM D, CRISTOFANILLI M. The landscape of targeted therapies in TNBC[J]. Cancers, 2020, 12(4):916.
[12] LI X, YANG J, PENG L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer[J]. Breast Cancer Res Treat, 2017, 161(2):279-287.
[13] NEDELJKOVIĆ M, DAMJANOVIĆ A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge[J]. Cells, 2019, 8(9):957.
[14] BOSCO J L, ANTONSEN S, SØRENSEN H T, et al. Metformin and incident breast cancer among diabetic women:a population-based case-control study in Denmark[J]. Cancer Epidemiol Biomarkers Prev, 2011, 20(1):101-111.
[15] AMORNRIT W, SANTIYANONT R. Effect of Amaranthus on advanced glycation end-products induced cytotoxicity and proinflammatory cytokine gene expression in SH-SY5Y cells[J]. Molecules, 2015, 20(9):17288-17308.
[16] LI S, CHEN C, XIONG X, et al. Type Iγ phosphatidylinositol phosphate kinase dependent cell migration and invasion are dispensable for tumor metastasis[J]. Am J Cancer Res, 2019, 9(5):959-974.
[17] YAO P, LI Y, SHEN W, et al. ANKHD1 silencing suppresses the proliferation, migration and invasion of CRC cells by inhibiting YAP1-induced activation of EMT[J]. Am J Cancer Res, 2018, 8(11):2311-2324.
[18] LEE J O, KANG M J, BYUN W S, et al. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51[J]. Breast Cancer Res, 2019, 21(1):115.
[19] LIU J, LI J, CHEN H, et al. Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the Hippo pathway[J]. J Cell Mol Med, 2020, 24(10):5786-5796.
[20] SOMASUNDARAM V, BASUDHAR D, BHARADWAJ G, et al. Molecular mechanisms of nitric oxide in cancer progression, signal transduction, and metabolism[J]. Antioxid Redox Signal, 2019, 30(8):1124-1143.
[21] FERRERI A J, CWYNARSKI K, PULCZYNSKI E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma:results of the first randomisation of the International Extranodal Lymphoma Study Group-32(IELSG32) phase 2 trial[J]. Lancet Haematol, 2016, 3(5):e217-e227.
[22] CAO C, ZHOU J Y, XIE S W, et al. Metformin enhances nomegestrol acetate suppressing growth of endometrial cancer cells and may correlate to downregulating mTOR activity in vitro and in vivo[J]. Int J Mol Sci, 2019, 20(13):3308.
[23] LEE J O, KANG M J, BYUN W S, et al. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51[J]. Breast Cancer Res, 2019, 21(1):115.
[24] 任翠, 贾丹, 吴霞, 等. 新型厚朴酚-二甲双胍缀合物对HepG2移植瘤小鼠抗肿瘤作用及机制研究[J]. 中药新药与临床药理, 2020, 31(3):257-263.